Infant Bacterial Therapeutics
98,4 SEK 0%Vær den første som følger denne virksomhed
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IBT B
Daglig lav / høj pris
98,4 / 99
SEK
Markedsværdi
1,33 mia. SEK
Aktieomsætning
2,36 mio. SEK
Volumen
24 t
Finanskalender
Delårsrapport
28.08.2024
Delårsrapport
14.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
SIX SIS AG, W8IMY | 11,0 % | 8,4 % |
Fjärde AP-fonden | 10,0 % | 7,7 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools